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Purpose Vaccination is considered a promising control measure against pandemic and epidemic influenza but has several limitations, mainly because of viral antigenic drift. Furthermore, the emergence of resistance to antiviral drugs in recent years limits the options available for the control of influenza. Under such circumstances, the interest in human monoclonal antibodies (HuMAbs) as alternative prophylactic and therapeutic agents has been strengthened by the recent identification of heretrosubtypic neutralizing HuMAbs to influenza viruses. Most of these HuMAbs have been derived from phage display libraries and found to target the HA stem region. However, HuMAbs generated by this method are the products of random recombination between the immunoglobulin variable region heavy chain and light chain genes.
In contrast, we have reported a cell-to-cell fusion method using a new fusion partner cell line, SPYMEG, and donor-derived peripheral blood mononuclear cells (PBMCs). In this study, we report the characterization of an anti-influenza HuMAb generated from the PBMCs of a volunteer vaccinated with seasonal influenza vaccine.
Methods/Results
Method: PBMCs were obtained from a healthy volunteer 7 and 14 days after receiving the trivalent seasonal influenza vaccine. The PBMCs were fused with SPYMEG cells to generate hybridomas. Ultimately, a hybridoma clone designated 5D7, which was derived from the PBMCs collected at 7 days after vaccination, was selected.
Result: The 5D7 secreted HuMAb that heterosubtypically cross-reacted with group 1 influenza A viruses, including seasonal H1N1, H1N1pdm and H9N2. In contrast, the HuMAb did not react with other group 1 viruses (such as H2N2 and H5N1), group 2 viruses or influenza B viruses. In accordance with the reactivity, the HuMAb showed cross-neutralizing activity against seasonal H1N1, H1N1pdm and H9N2 influenza virus strains. An HI assay showed that the HuMAb had HI activity against both seasonal H1N1 and H1N1pdm. Western blotting analysis also showed that the HuMAb recognized A/Suita/1/2009 HA under non-reducing conditions but had no such reactivity under reducing conditions. Selection of escape mutant showed that the HuMAb recognizes a novel epitope region (residues 112-118) in the HA head region, which is distinct from epitopes recognized by the heterosubtypic neutralizing HuMAbs against influenza viruses reported previously. A database search also revealed that the epitope sequences are highly conserved among H1 and H9 viruses.
Conclusion
Several heterosubtypic neutralizing HuMAbs with broad spectrum activity against influenza A viruses have been described recently. Most of the HuMAbs were isolated from phage display libraries and recognized conserved epitopes located in the HA stem region. In contrast, information about conserved epitopes located in the HA globular head region is rather limited. Thus, it is not known whether equivalent HuMAbs that target the globular head region are produced in the course of the immune response to influenza virus. The main finding of this study is that heterosubtypic neutralizing IgG antibodies that target HA globular head can be elicited in humans following exposure to seasonal influenza vaccine.
In addition, Most heterosubtypic cross-neutralizing HuMAb have been reported to recognize epitopes located mainly in the most conserved HA stem region. To our knowledge, 5D7 is the first heterosubtypic neutralizing HuMAb that targets a conserved epitope distinct from the RBS in the HA globular head region. Thus, the HuMAb reported here may be a potential candidate for the future development of effective anti-influenza prophylactic and therapeutic antibodies. In addition, our findings of a novel epitope that is highly conserved in the HA globular head of H1 and H9 influenza viruses should provide useful information for designing and developing a universal vaccine against influenza viruses.
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